5 Stocks Moving The Health Care Sector Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 147 points (1.0%) at 15,587 as of Thursday, Feb. 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,311 issues advancing vs. 626 declining with 152 unchanged.

The Health Care sector currently sits up 0.8% versus the S&P 500, which is up 1.0%. Top gainers within the sector include Smith & Nephew ( SNN), up 2.2%, Grifols ( GRFS), up 2.1%, Regeneron Pharmaceuticals ( REGN), up 2.0%, Biogen Idec ( BIIB), up 1.9% and Shire ( SHPG), up 1.8%. On the negative front, top decliners within the sector include Perrigo Company ( PRGO), down 3.5%, AstraZeneca ( AZN), down 2.1%, Sanofi ( SNY), down 1.8% and Teva Pharmaceutical Industries ( TEVA), down 1.6%.

TheStreet would like to highlight 5 stocks pushing the sector higher today:

5. Mettler-Toledo International ( MTD) is one of the companies pushing the Health Care sector higher today. As of noon trading, Mettler-Toledo International is up $14.09 (6.0%) to $249.96 on heavy volume. Thus far, 214,650 shares of Mettler-Toledo International exchanged hands as compared to its average daily volume of 185,300 shares. The stock has ranged in price between $242.20-$254.96 after having opened the day at $242.20 as compared to the previous trading day's close of $235.87.

Mettler-Toledo International Inc. supplies precision instruments and services worldwide. The company operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. Mettler-Toledo International has a market cap of $7.1 billion and is part of the health services industry. Shares are down 2.8% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate Mettler-Toledo International a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Mettler-Toledo International as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Mettler-Toledo International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Incyte ( INCY) is up $1.67 (2.7%) to $63.93 on average volume. Thus far, 810,529 shares of Incyte exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $62.57-$64.35 after having opened the day at $62.63 as compared to the previous trading day's close of $62.26.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $10.1 billion and is part of the drugs industry. Shares are up 23.0% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts who rate Incyte a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk. Get the full Incyte Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Stryker Corporation ( SYK) is up $1.04 (1.4%) to $78.04 on average volume. Thus far, 852,232 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $77.17-$78.23 after having opened the day at $77.28 as compared to the previous trading day's close of $77.00.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Stryker Corporation has a market cap of $29.0 billion and is part of the health services industry. Shares are up 2.5% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts who rate Stryker Corporation a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Stryker Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Vertex Pharmaceuticals ( VRTX) is up $1.10 (1.4%) to $78.51 on light volume. Thus far, 455,672 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $76.24-$79.24 after having opened the day at $76.45 as compared to the previous trading day's close of $77.41.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $18.5 billion and is part of the drugs industry. Shares are up 4.2% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Alexion Pharmaceuticals ( ALXN) is up $1.57 (1.0%) to $156.06 on light volume. Thus far, 429,328 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $153.72-$156.14 after having opened the day at $154.33 as compared to the previous trading day's close of $154.49.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $30.6 billion and is part of the drugs industry. Shares are up 17.6% year-to-date as of the close of trading on Wednesday. Currently there are 17 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Alexion Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria

Health Care and Pharma Feeling the Wrath of Trump: Cramer's 'Mad Money' Recap (Wednesday 1/11/17)

Health Care and Pharma Feeling the Wrath of Trump: Cramer's 'Mad Money' Recap (Wednesday 1/11/17)

Berkshire Hathaway, SAP, Dominion Resources: 'Mad Money' Lightning Round

Berkshire Hathaway, SAP, Dominion Resources: 'Mad Money' Lightning Round

These 5 Health Care Stocks Are Breaking Out This Christmas

These 5 Health Care Stocks Are Breaking Out This Christmas

Analysts' Actions -- AK Steel, Mettler-Toledo, Pure Storage, Phillips 66 and More

Analysts' Actions -- AK Steel, Mettler-Toledo, Pure Storage, Phillips 66 and More